Edwards Lifesciences Corporation logo
EWEdwards Lifesciences Corporation

Revenue

Trailing-twelve-month (TTM) revenue is $6.30 Billion with a year-over-year growth of +13.81%. Revenue represents the total income generated from the company's primary business operations.

Revenue

EW Revenue

$1.65B

Reported quarterly revenue; no daily interpolation.

+19.81% 5Y

EW Quarterly Revenue Growth (YoY)

Revenue growth vs the same quarter one year earlier, last 20 quarters.

EW Revenue by Segment

How EW’s revenue breaks down across its reported segments in the latest reported fiscal year.

By product / business (FY 2025)

  • Transcatheter Heart Valves$4.49B74.0%
  • Surgical Heart Valve Therapy$1.03B17.0%
  • Transcatheter Mitral And Tricuspid Therapies$550.60M9.1%

By geography (FY 2025)

  • United States$3.54B58.4%
  • Europe$1.52B25.0%
  • Rest of World$652.30M10.8%
  • Japan$354.70M5.8%

EW Revenue by Product / Business (history)

How the revenue mix has shifted across the last 6 reported fiscal years. Bar height tracks total revenue.

Transcatheter Heart Valves · FY2020: $2.9BSurgical Heart Valve Therapy · FY2020: $762MTranscatheter Mitral And Tricuspid Therapies · FY2020: $42MOther reported · FY2020: $725MFY20Transcatheter Heart Valves · FY2021: $3.4BSurgical Heart Valve Therapy · FY2021: $889MTranscatheter Mitral And Tricuspid Therapies · FY2021: $86MOther reported · FY2021: $835MFY21Transcatheter Heart Valves · FY2022: $3.5BSurgical Heart Valve Therapy · FY2022: $893MTranscatheter Mitral And Tricuspid Therapies · FY2022: $116MOther reported · FY2022: $855MFY22Transcatheter Heart Valves · FY2023: $3.9BSurgical Heart Valve Therapy · FY2023: $999MTranscatheter Mitral And Tricuspid Therapies · FY2023: $198MOther reported · FY2023: $928MFY23Transcatheter Heart Valves · FY2024: $4.1BSurgical Heart Valve Therapy · FY2024: $981MTranscatheter Mitral And Tricuspid Therapies · FY2024: $352MFY24Transcatheter Heart Valves · FY2025: $4.5BSurgical Heart Valve Therapy · FY2025: $1.0BTranscatheter Mitral And Tricuspid Therapies · FY2025: $551MFY25
  • Transcatheter Heart Valves
  • Surgical Heart Valve Therapy
  • Transcatheter Mitral And Tricuspid Therapies
  • Other reported

Bars in years without a matched total revenue show the share of reported segments only.

EW Revenue by Geography (history)

How the revenue mix has shifted across the last 6 reported fiscal years. Bar height tracks total revenue.

United States · FY2020: $2.5BEurope · FY2020: $974MRest of World · FY2020: $436MJapan · FY2020: $460MFY20United States · FY2021: $3.0BEurope · FY2021: $1.2BRest of World · FY2021: $550MJapan · FY2021: $529MFY21United States · FY2022: $3.1BEurope · FY2022: $1.2BRest of World · FY2022: $601MJapan · FY2022: $474MFY22United States · FY2023: $3.5BEurope · FY2023: $1.3BRest of World · FY2023: $709MJapan · FY2023: $452MFY23United States · FY2024: $3.2BEurope · FY2024: $1.3BRest of World · FY2024: $572MJapan · FY2024: $340MFY24United States · FY2025: $3.5BEurope · FY2025: $1.5BRest of World · FY2025: $652MJapan · FY2025: $355MFY25
  • United States
  • Europe
  • Rest of World
  • Japan

Bars in years without a matched total revenue show the share of reported segments only.

Revenue (TTM)

$6.30B

$6.30 Billion

Year-over-Year Growth

+13.81%

vs. $5.54B a year ago (TTM)

Revenue CAGR

+7.10%

5 Year compound annual growth rate

Revenue CAGR (Compound Annual Growth Rate)

1 Year

+13.81%

3 Year

+4.64%

5 Year

+7.10%

10 Year

+9.26%

15 Year

+9.99%

20 Year

+9.61%

CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.

Annual Revenue History

YearRevenueYoY Change% Change
2025$6.07B+$628.10M+11.55%
2024$5.44B+$429.50M+8.57%
2023$5.01B($372.40M)(6.92%)
2022$5.38B+$149.90M+2.86%
2021$5.23B+$846.20M+19.29%
2020$4.39B+$38.30M+0.88%
2019$4.35B+$625.20M+16.79%
2018$3.72B+$287.50M+8.37%
2017$3.44B+$471.60M+15.91%
2016$2.96B+$470.00M+18.85%

Revenue Growth Summary

TTM Growth

+13.81%

3-Year Avg Growth

+4.64%

5-Year Avg Growth

+7.10%

Data as of Sunday, June 28, 2026

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

Irvine, CA
15,800 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Bernard J. Zovighian